VolitionRx (NYSE:VNRX) Stock Price Down 8.5% – Here’s What Happened

VolitionRx Limited (NYSE:VNRX)’s stock price dropped 8.5% during trading on Wednesday . The company traded as low as $0.2203 and last traded at $0.2241. Approximately 2,703,295 shares traded hands during trading, an increase of 10% from the average daily volume of 2,460,498 shares. The stock had previously closed at $0.2450.

Analysts Set New Price Targets

VNRX has been the topic of a number of recent research reports. HC Wainwright decreased their target price on VolitionRx from $2.50 to $1.50 and set a “buy” rating on the stock in a report on Monday, November 17th. Maxim Group cut VolitionRx from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $3.00 price objective on shares of VolitionRx in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $2.50.

VolitionRx Stock Performance

The stock has a market capitalization of $29.36 million, a PE ratio of -0.62 and a beta of 1.29. The firm has a 50 day moving average of $0.28 and a 200-day moving average of $0.45.

Institutional Trading of VolitionRx

Institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC grew its position in VolitionRx by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the company’s stock valued at $6,367,000 after purchasing an additional 887,351 shares in the last quarter. Lagoda Investment Management L.P. grew its holdings in shares of VolitionRx by 6.7% during the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the company’s stock valued at $8,476,000 after acquiring an additional 782,000 shares in the last quarter. Citadel Advisors LLC increased its stake in shares of VolitionRx by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock worth $224,000 after acquiring an additional 135,775 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of VolitionRx by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the company’s stock worth $246,000 after acquiring an additional 85,816 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in VolitionRx during the second quarter valued at $52,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.